These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 10767352)

  • 1. Identification of activated tumor antigen-reactive CD8+ cells in healthy individuals.
    Lee TV; Anderson BW; Peoples GE; Castilleja A; Murray JL; Gershenson DM; Ioannides CG
    Oncol Rep; 2000; 7(3):455-66. PubMed ID: 10767352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stimulation of cells from a non-invaded and an invaded lymph node with a HER-2+ tumor with peptides corresponding to T-cell epitopes E75 and G89 induced expansion of central memory cells (TCM) from the metastasis-negative lymph nodes.
    Ko BK; Efferson CL; Kawano K; Kuerer HM; Sahin A; Murray JL; Ioannides CG
    Int J Oncol; 2004 Jun; 24(6):1413-8. PubMed ID: 15138582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The comparison of cytotoxic T-lymphocyte effects of dendritic cells stimulated by the folate binding protein peptide cultured with IL-15 and IL-2 in solid tumor.
    Kim DK; Kim JH; Kim YT; Kim JW; Ioannides CG
    Yonsei Med J; 2002 Dec; 43(6):691-700. PubMed ID: 12497651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of tumor-reactive CTL by C-side chain variants of the CTL epitope HER-2/neu protooncogene (369-377) selected by molecular modeling of the peptide: HLA-A2 complex.
    Castilleja A; Carter D; Efferson CL; Ward NE; Kawano K; Fisk B; Kudelka AP; Gershenson DM; Murray JL; O'Brian CA; Ioannides CG
    J Immunol; 2002 Oct; 169(7):3545-54. PubMed ID: 12244144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stimulation of human T cells by an influenza A vector expressing a CTL epitope from the HER-2/neu protooncogene results in higher numbers of antigen-specific TCRhi cells than stimulation with peptide. Divergent roles of IL-2 and IL-15.
    Efferson CL; Kawano K; Tsuda N; Palese P; García-Sastre A; Ioannides CG
    Anticancer Res; 2005; 25(2A):715-24. PubMed ID: 15868901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of tumor antigen-specific cytotoxic T lymphocytes (CTLs) by human dendritic cells infected with an attenuated influenza A virus expressing a CTL epitope derived from the HER-2/neu proto-oncogene.
    Efferson CL; Schickli J; Ko BK; Kawano K; Mouzi S; Palese P; García-Sastre A; Ioannides CG
    J Virol; 2003 Jul; 77(13):7411-24. PubMed ID: 12805440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER-2 peptides p776 and F7, N-terminal-linked with Ii-Key tetramer (LRMK) help the proliferation of E75-TCR+ cells: The dependency of help on the side chains of LRMK-extended peptide pointed towards the T cell receptor.
    Li Y; Ishiyama S; Matsueda S; Tsuda N; Ioannides CG
    Oncol Rep; 2008 Jun; 19(6):1445-52. PubMed ID: 18497949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secretion of CXC chemokine IP-10 by peripheral blood mononuclear cells from healthy donors and breast cancer patients stimulated with HER-2 peptides.
    Lee TV; Kim DK; Peoples GE; Castilleja A; Murray JL; Gershenson DM; Ioannides CG
    J Interferon Cytokine Res; 2000 Apr; 20(4):391-401. PubMed ID: 10805374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial.
    Mittendorf EA; Storrer CE; Foley RJ; Harris K; Jama Y; Shriver CD; Ponniah S; Peoples GE
    Cancer; 2006 Jun; 106(11):2309-17. PubMed ID: 16596621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines.
    Fisk B; Blevins TL; Wharton JT; Ioannides CG
    J Exp Med; 1995 Jun; 181(6):2109-17. PubMed ID: 7539040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Helper peptide G89 (HER-2:777-789) and G89-activated cells regulate the survival of effectors induced by the CTL epitope E75 (HER-2, 369-377). Correlation with the IFN-gamma: IL-10 balance.
    Lee TV; Johnston DA; Thomakos N; Honda T; Efferson CL; Ioannides CG
    Anticancer Res; 2002; 22(3):1481-90. PubMed ID: 12168827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folate binding protein peptide 191-199 presented on dendritic cells can stimulate CTL from ovarian and breast cancer patients.
    Kim DK; Lee TV; Castilleja A; Anderson BW; Peoples GE; Kudelka AP; Murray JL; Sittisomwong T; Wharton JT; Kim JW; Ioannides CG
    Anticancer Res; 1999; 19(4B):2907-16. PubMed ID: 10652572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer.
    Murray JL; Gillogly ME; Przepiorka D; Brewer H; Ibrahim NK; Booser DJ; Hortobagyi GN; Kudelka AP; Grabstein KH; Cheever MA; Ioannides CG
    Clin Cancer Res; 2002 Nov; 8(11):3407-18. PubMed ID: 12429628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity.
    Kemp RA; Ronchese F
    J Immunol; 2001 Dec; 167(11):6497-502. PubMed ID: 11714817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
    Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
    Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitivity of undifferentiated, high-TCR density CD8+ cells to methylene groups appended to tumor antigen determines their differentiation or death.
    Kawano K; Efferson CL; Peoples GE; Carter D; Tsuda N; Murray JL; Ioannides CG
    Cancer Res; 2005 Apr; 65(7):2930-7. PubMed ID: 15805296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cells generated either from CD34+ progenitor cells or from monocytes differ in their ability to activate antigen-specific CD8+ T cells.
    Ferlazzo G; Wesa A; Wei WZ; Galy A
    J Immunol; 1999 Oct; 163(7):3597-604. PubMed ID: 10490952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polyactin A is a novel and potent immunological adjuvant for peptide-based cancer vaccine.
    Wang W; Li Y; Wang Y; Ren S; Li Y; Wang B
    Int Immunopharmacol; 2018 Jan; 54():95-102. PubMed ID: 29112895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional supertype of HLA-A2 in the presentation of Flu matrix p58-66 to induce CD8+ T-cell response in a Northern Chinese population.
    Zhang HG; Pang XW; Shang XY; Xing Q; Chen WF
    Tissue Antigens; 2003 Oct; 62(4):285-95. PubMed ID: 12974795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of populations of antigen-specific cytotoxic T cells using DCs transfected with DNA construct encoding HER2/neu tumor antigen epitopes.
    Kuznetsova M; Lopatnikova J; Khantakova J; Maksyutov R; Maksyutov A; Sennikov S
    BMC Immunol; 2017 Jun; 18(1):31. PubMed ID: 28633645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.